Close Menu

Editor's Pick

The company's technology uses CRISPR to deplete unwanted nucleic acid sequences from NGS libraries, leaving behind targets of interest.

The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.

The method uses standard lab equipment and the nanoswitches can be easily reconfigured and made in large batches at a cost of about $0.01 per reaction.

The community is poised to be the primary channel for stakeholders to communicate PGx concerns with FDA, but it is unclear if all stakeholders will participate.

Driving the shift is a belief that standard STR testing is not always a reliable tool for determining complex family relationships.

An international team of researchers put nine immune cell sequencing methods head to head, including RNA-based and DNA-based ones, using the same T-cell sample.

Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.

The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.

The move raises questions about what precisely is an LDT outside of FDA jurisdiction and heightens concerns that poorly validated tests will enter the market and endanger public health.

Mount Sinai researchers investigated four cytokine proteins and found that two of them were elevated in the serum samples of SARS-CoV-2 patients who fared the worst.

Pages

Nature News writes that additional details about the UK plan for an agency to support high-risk, high-reward science are needed.

The New York Times reports that the US Food and Drug Administration has authorized Johnson & Johnson's SARS-CoV-2 vaccine.

The Wall Street Journal writes new studies are giving glimpses into the origins of SARS-CoV-2.

In PLOS this week: analysis of Plasmodium population structure, qPCR assay to diagnose scabies, and more.